The DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Atypical aging in down syndrome
Abstract
At present, there may be over 210,000 people with Down syndrome (DS) over the age of 55 in the United States (US) who have significant needs for augmented services due to circumstances related to ordinary and/or pathological aging. From 1979 through 2003, the birth prevalence of DS rose from 9.0 to 11.8 (31.1%) per 10,000 live births in 10 representative US regions. This increase, largely due to women conceiving after age 35, portends an ever‐growing population of people with DS who may be subject to pathogenic aging. Whereas Trisomy 21 is one of the most widespread genetic causes of intellectual disability (ID), it still is one of the least understood of all genetic ID syndromes. While longevity in people with DS has improved appreciably in as modest a period as 30 years, age‐specific risk for mortality still is considerably increased compared both with other people with ID or with the typically developing population. The penetrance of the phenotype is widely distributed, even though a consistent genotype is assumed in 95% of the cases. Some, but not all body systems, exhibit signs of premature or accelerated aging. This may be due to both genetic and epigenetic inheritance. We now know that the long‐term outcome for people with DS is not as ominous as once contemplated; a number of people with DS are living into their late 60s and 70s with few if any major signs of pathogenic aging. Alzheimer's disease (AD), a devastating disease that robs a person of their memory, abilities and personality, is particularly common in elder adults with DS, but is not a certainty as originally thought, some 20% to 30% of elder adults with DS might never show any, or at most mild signs of AD. DS has been called a mature well‐understood syndrome, not in need of further research or science funding. We are only beginning to understand how epigenetics affects the phenotype and it may be feasible in the future to alter the phenotype through epigenetic interventions. This chapter is divided into two sections. The first section will review typical and atypical aging patterns in somatic issues in elder adults with DS; the second section will review the multifaceted relationship between AD and DS. © 2013 Wiley Periodicals, Inc. Dev Disabil Res Rev 2013;18:51–67.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–211 of 211
Genetic and Epigenetic Dysregulation of Imprinted Genes In The Brain
Kernohan, K. D., & Bérubé, N. G. (2010) · Epigenomics · doi:10.2217/epi.10.61 · Cited by 22
The Extended Tau Haplotype and the Age of Onset of Dementia in Down Syndrome
Jones, E. L., Margallo‐Lana, M., Prasher, V. P., & Ballard, C. G. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000152044 · Cited by 22
Donepezil for dementia in people with Down syndrome
Mohan, M., Carpenter, P. K., & Bennett, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007178 · Cited by 22
ApoE2 Allele, Down's Syndrome, and Dementiaa
Royston, M. C., Mann, D. M. A., Pickering-Brown, S. M., Owen, F., Perry, R., RAGBHAVAN, R., Khin-Nu, C., Tyner, S., DAY, K., Crook, R., et al. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34428.x · Cited by 20
Mandava, S., Koppaka, N. T., Bhatia, V., & Das, B. R. (2010) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2009.0167 · Cited by 20
The scientific activities of Alexander Fleming, other than the discovery of penicillin
Hare, R. (1983) · Medical History · doi:10.1017/s0025727300043386 · Cited by 19
An Objective Appraisal of the Free Radical Theory of Aging
Lustgarten, M. S., Müller, F. L., & Remmen, H. V. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-378638-8.00008-7 · Cited by 18
Wang, L., Yang, W., Ju, W., Wang, P., Zhao, X., Jenkins, E. C., Brown, W. T., & Zhong, N. A. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.056 · Cited by 18
Cellular ageing of Alzheimer's disease and Down syndrome cells in culture.
Carmeliet, G., David, G., & Cassiman, J. (1991) · Mutation research · doi:10.1016/0921-8734(91)90013-2 · Cited by 12
Total serum cholesterol levels and Alzheimer's dementia in patients with down syndrome
Prasher, V. P., Airuehia, E., Patel, A., & Haque, S. M. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2014 · Cited by 11
Abbeduto (2004) · doi:10.1352/0895-8017(2004)109
Cited by
Predicting Age Using Neuroimaging: Innovative Brain Ageing Biomarkers
Cole, J. H., & Franke, K. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.10.001 · Cited by 903
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562
Accelerated epigenetic aging in Down syndrome
Horvath, S., Garagnani, P., Bacalini, M. G., Pirazzini, C., Salvioli, S., Gentilini, D., Di Blasio, A. M., Giuliani, C., Tung, S., Vinters, H. V., et al. (2015) · Aging Cell · doi:10.1111/acel.12325 · Cited by 488
Brain age and other bodily ‘ages’: implications for neuropsychiatry
Cole, J. H., Marioni, R. E., Harris, S. E., & Deary, I. J. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0098-1 · Cited by 440
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Metadata
- Authors
- Zigman, W. B.
- Venue
- Developmental Disabilities Research Reviews
- Publisher
- Wiley
- Published
- 2013-08
- Volume
- 18
- Issue
- 1
- Pages
- 51-67
- ISSN
- 1940-5510 (ISSN-L)
- 1940-5529
- OpenAlex
- W1575011814
- Cited by
- 260
- References
- 211
- FWCI
- 21.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.